<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00108823</url>
  </required_header>
  <id_info>
    <org_study_id>BY217/M2-121</org_study_id>
    <nct_id>NCT00108823</nct_id>
  </id_info>
  <brief_title>The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)</brief_title>
  <official_title>A 24-week, Double Blind, Randomized Study to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Parameters Indicative of Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the effects of roflumilast on lung function parameters&#xD;
      indicative of hyperinflation in patients with COPD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung function parameters indicative of hyperinflation in patients with COPD</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from randomization to endpoint in additional pre and post bronchodilator spirometric and lung volume parameters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of quality of life parameters and dyspnea</measure>
  </secondary_outcome>
  <enrollment>550</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease, COPD</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Patients with a history of chronic obstructive pulmonary disease for at least 12&#xD;
             months as defined by the GOLD (Global Initiative on Obstructive Lung Diseases)&#xD;
             criteria (2003)&#xD;
&#xD;
          -  Age ≥ 40 years&#xD;
&#xD;
          -  FEV1/FVC ratio (post-bronchodilator) ≤ 70%&#xD;
&#xD;
          -  FEV1 (post-bronchodilator) ≤ 65% of predicted&#xD;
&#xD;
          -  FRC (post-bronchodilator) ≤ 120% of predicted&#xD;
&#xD;
          -  Clinically stable COPD within 4 weeks prior to baseline visit (B0).&#xD;
&#xD;
          -  Availability of a chest x-ray dated a maximum of 6 months prior to study baseline&#xD;
             visit (B0) or a willingness to have a chest x-ray performed at visit (B0).&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  COPD exacerbation indicated by a treatment with systemic glucocorticosteroids not&#xD;
             stopped at least 4 weeks prior to the baseline visit (B0)&#xD;
&#xD;
          -  Non smoker, current smoker or ex-smoker (smoking cessation at least one year ago) with&#xD;
             a smoking history of &lt; 10 pack years&#xD;
&#xD;
          -  Suffering from any concomitant disease that might interfere with study procedures or&#xD;
             evaluation&#xD;
&#xD;
          -  Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit&#xD;
             (B0)&#xD;
&#xD;
          -  Diagnosis of asthma and/or other relevant lung disease (e.g. history of&#xD;
             bronchiectasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer,&#xD;
             interstitial lung disease [e.g. fibrosis, silicosis, sarcoidosis], and active&#xD;
             tuberculosis)&#xD;
&#xD;
          -  Current participation in a pulmonary rehabilitation program or completion of a&#xD;
             pulmonary rehabilitation program within 2 months preceding the baseline visit (B0).&#xD;
&#xD;
          -  Known alpha-1-antitrypsin deficiency&#xD;
&#xD;
          -  Need for long term oxygen therapy defined as ≥ 15 hours/day&#xD;
&#xD;
          -  Clinically relevant abnormal laboratory values suggesting an unknown disease and&#xD;
             requiring further clinical evaluation (as assessed by the investigator)&#xD;
&#xD;
          -  Known infection with HIV, active hepatitis and/or liver insufficiency&#xD;
&#xD;
          -  Diagnosis or history of cancer (other than basal cell carcinoma) or recurrence within&#xD;
             5 years prior to study start&#xD;
&#xD;
          -  Clinically significant cardiopulmonary abnormalities (diagnosed clinically or by&#xD;
             x-ray/ECG) that are not related to COPD and that require further evaluation&#xD;
&#xD;
          -  Pregnancy, breast feeding, oocyte donation or oocyte implantation planned during the&#xD;
             trial&#xD;
&#xD;
          -  The female patient is of childbearing potential and is not using and is not willing to&#xD;
             continue to use a medically reliable method of contraception for the entire study&#xD;
             duration, such as oral, injectable, or implantable contraceptives, or intrauterine&#xD;
             contraceptive devices, unless she is surgically sterilized/hysterectomized or&#xD;
             post-menopausal &gt; 1 year or any other criteria considered sufficiently reliable by the&#xD;
             investigator in individual cases&#xD;
&#xD;
          -  Participation in another study (use of investigational product) within 30 days&#xD;
             preceding the baseline visit (B0) or re-entry of patients already enrolled in this&#xD;
             trial&#xD;
&#xD;
          -  Suspected inability or unwillingness to comply with study procedures&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Inability to follow study procedures due to, for example, language problems or&#xD;
             psychological disorders&#xD;
&#xD;
          -  Use of prohibited drugs&#xD;
&#xD;
          -  Suspected hypersensitivity to the study medication and/or contraindication to any&#xD;
             ingredients of the study medication (roflumilast) or rescue medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in California</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Colorado</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Florida</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Missouri</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in New Mexico</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Oregeon</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in South Carolina</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Texas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Washington</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Canada</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in France</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Poland</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in South Africa</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in Spain</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALTANA Pharma</name>
      <address>
        <city>Cities in the United Kingdom</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Portugal</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4479&amp;filename=BY217-M2-121-RDS-2008-12-23.pdf</url>
    <description>BY217-M2-121-RDS-2008-12-23.pdf</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>April 19, 2005</study_first_submitted>
  <study_first_submitted_qc>April 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2005</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

